Abstract
In 1989, the Scottish melanoma group initiated a randomized trial, comparing observation alone with 6 months' therapy with low dose interferon α (given subcutaneously 3 MU day–1, thrice weekly), for patients with primary melanomas of at least 3 mm Breslow thickness, or with evidence of regional node involvement. The trial was closed in 1993 with only 95 eligible patients randomized. There were no toxic deaths, and no patient failed to complete the treatment for reasons of toxicity. 6 months' treatment with low-dose interferon-α resulted in a statistically significant improved disease-free survival for up to 24 months after randomization (P< 0.05). However, at a median follow-up of over 6 years, although there was an apparent improvement in disease-free survival (from 9 to 22 months), and overall survival (from 27 to 39 months), consistent with larger studies powered to detect such differences, these differences were not statistically significant. The data therefore suggest that 6 months of low-dose interferon is active, and confirm the importance of the large randomized studies, such as the UKCCCR AIM-High and EORTC trials, that seek to confirm a possible survival advantage for low or intermediate dose interferon. © 2001 Cancer Research Campaign http://www.bjcancer.com
Keywords: adjuvant, interferon, melanoma, Scottish trial
Full Text
The Full Text of this article is available as a PDF (77.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Grob J. J., Dreno B., de la Salmonière P., Delaunay M., Cupissol D., Guillot B., Souteyrand P., Sassolas B., Cesarini J. P., Lionnet S. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998 Jun 27;351(9120):1905–1910. doi: 10.1016/s0140-6736(97)12445-x. [DOI] [PubMed] [Google Scholar]
- Kirkwood J. M., Ibrahim J. G., Sondak V. K., Richards J., Flaherty L. E., Ernstoff M. S., Smith T. J., Rao U., Steele M., Blum R. H. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000 Jun;18(12):2444–2458. doi: 10.1200/JCO.2000.18.12.2444. [DOI] [PubMed] [Google Scholar]
- Kirkwood J. M., Strawderman M. H., Ernstoff M. S., Smith T. J., Borden E. C., Blum R. H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996 Jan;14(1):7–17. doi: 10.1200/JCO.1996.14.1.7. [DOI] [PubMed] [Google Scholar]
- Legha S. S. Interferons in the treatment of malignant melanoma. A review of recent trials. Cancer. 1986 Apr 15;57(8 Suppl):1675–1677. doi: 10.1002/1097-0142(19860415)57:8+<1675::aid-cncr2820571307>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
- MacKie R., Hunter J. A., Aitchison T. C., Hole D., Mclaren K., Rankin R., Blessing K., Evans A. T., Hutcheon A. W., Jones D. H. Cutaneous malignant melanoma, Scotland, 1979-89. The Scottish Melanoma Group. Lancet. 1992 Apr 18;339(8799):971–975. doi: 10.1016/0140-6736(92)91539-k. [DOI] [PubMed] [Google Scholar]
- Pehamberger H., Soyer H. P., Steiner A., Kofler R., Binder M., Mischer P., Pachinger W., Auböck J., Fritsch P., Kerl H. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol. 1998 Apr;16(4):1425–1429. doi: 10.1200/JCO.1998.16.4.1425. [DOI] [PubMed] [Google Scholar]
- Rusciani L., Petraglia S., Alotto M., Calvieri S., Vezzoni G. Postsurgical adjuvant therapy for melanoma. Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up. Cancer. 1997 Jun 15;79(12):2354–2360. doi: 10.1002/(sici)1097-0142(19970615)79:12<2354::aid-cncr9>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]